PeerVoice Oncology & Haematology Video: Recent Episodes
PeerVoice
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours
Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML
Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice
Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals
Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts
Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED
Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting
Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer
Christine Brezden-Masley, MD, PhD, FRCPC - Breaking Barriers: Expert Guidance on Best Strategies for Biomarker Testing in Gastric and GEJ Cancers
Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events
Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence
Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes
Alon Altman, MD, FRCSC - Upping the Ante in Advanced Endometrial Cancer Care: Optimizing the Use of Immunotherapy to Improve Patient Outcomes
Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
Christine Brezden-Masley, MD, PhD, FRCPC - Navigating HER2+ Early Breast Cancer Care: A Multidisciplinary Roadmap to Better Survival
Stephanie Snow, MD, FRCPC - Mastering HER2 in GI Malignancies: Immunotherapy and Chemotherapy Backbones for Optimal Patients Outcomes
Teresa Tiano, Honours B.A. - A Challenging Journey: A Patient-Centred Perspective on Gastric Cancer
Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML
Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer
Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem
Ravi Ramjeesingh, MD, PhD, FRCPC - Immunotherapy for Biliary Tract Cancers: Changing the Narrative in Rare and Aggressive Tumours
Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024
David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey
Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients
Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma
María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance
Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC
Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization
Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy
Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
Abdulazeez Salawu, MBBS, MSc, PhD - The Case for Biomarker-Guided Management of mCRC: Steps to Refine Care Along the Patient’s Journey
Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer
Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?
Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes
Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs
George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action
Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey
Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line
Paul Wheatley-Price, MBChB, MD - The Track to Better Outcomes: Identifying and Managing Patients With NTRK-Positive Solid Tumours
Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey
Shawn Malone, MD, FRCPC - Maximizing Survival in mCRPC: Case-Based Guidance to Optimize Sequencing Decisions
Michael Chu, MD - A Smooth Ride: How to Optimize the Patient Journey With CAR T-Cell Therapy in Multiple Myeloma
Donna E. Reece, MD - Cases in Relapsed Refractory Multiple Myeloma: The Role of Anti-CD38–Based Regimens in an Evolving Canadian Landscape
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
Normand Blais, MD - Adjuvant Immunotherapy in Patients With Solid Tumours: Addressing Challenges With System Capacity in the Canadian Healthcare Setting
Eric Legius, MD, PhD - Building Blocks for Better Management of NF-1–Associated Plexiform Neurofibromas: Integrating New Evidence Into Canadian Clinical Practice
Brandon Sheffield, MD, FRCPC - Identifying Actionable Targets in Solid Tumours: The Importance of Comprehensive Genomic Profiling
Christine Simmons, MD, MSc, FRCPC - Managing HR+/HER2- Metastatic Breast Cancer in the Community: Optimizing Safety to Maximize Benefit
Steven Mark Taylor, MD, FRCS(C), FACS - Beyond Face Value: The Case for Considering Immunotherapy in Locally Advanced cSCC
Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations
Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape
Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not
Angela Lamarca, MD, PhD, MSc - Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplinary Care, Molecular Testing, and Targeted Treatment
Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma
Aly-Khan A. Lalani, BSc(Hons), MD, FRCPC - Tailoring Immunotherapy-Based Combination Treatment in Advanced RCC: Key Updates to Refine Care
Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers
Karim Fizazi, MD, PhD - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment
Richard LeBlanc, MD - BCMA-Targeted Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Why, Who, and When
Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma
Kim N. Chi, MD, FRCPC / Steven Yip, MD, MSc, FRCPC - Personalizing Treatment Selection, Sequencing, and Future Opportunities for Patients With Advanced Prostate Cancer
Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care
Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
Anna Tinker, MD, FRCPC - Maximizing Survival in Advanced or Recurrent Endometrial Cancer: The Evolving Role of Immunotherapy
Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC
Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma
Julie Stakiw, MD, FRCPC - Frailty Assessment and Improved Care in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients
Barbara Melosky, MD, FRCPC - Narrowing the Care Gap in NSCLC With Rare EGFR Alterations: The Next Frontier in Precision Medicine
Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
Stephen Chia, MD, FRCPC - Exploring the Role of Immunotherapy in Triple-Negative Breast Cancer: A Turning Point for a Difficult-to-Treat Disease?
Barbara Melosky, MD, FRCPC - Navigating Recent Updates With Immunotherapy for Advanced NSCLC: Guidance to Optimize Treatment Decisions
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?
Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
Stephen Chia, MD, FRCP(C) - Keeping Abreast of the Latest Advances in HER2-Positive Metastatic Breast Cancer Treatment: Clinical Implications for the Canadian Landscape
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
Stephanie Snow, MD, FRCPC - First-Line Immunotherapy in Advanced Non-Small Cell Lung Cancer: Discussing a Game Plan
Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
Hira Mian, MD, MSc, FRCPC - Moving the Needle in Relapsed Multiple Myeloma: Expert Insights to Address Key Questions in Patient Care
Laurie H. Sehn, MD, MPH - Clinical Update in the Treatment of Mantle Cell Lymphoma: The Evolving Evidence of BTK Inhibitors
John Storring, MD, CM, FRCPC - Current Therapeutic Strategies for Targeted Therapy Selection in De Novo Acute Myeloid Leukemia
Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care
Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors
Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?
Thomas Powles, MBBS, MRCP, MD - Education, Collaboration and Communication: Aligning Patient and Clinical Priorities in Locally Advanced and Metastatic Urothelial Carcinoma
Alicia K. Morgans, MD, MPH - What Would You Do Next? Exploring Expert Perspectives on Clinical Cases and Compelling Questions in mHSPC and nmCRPC
Vijay Ramaswamy, MD, PhD, FRCPC - Managing the Pediatric Patient With Plexiform Neurofibromas: The Case for Systemic Therapy
Mary Frances McMullin, MD, FRCP, FRCPath - Managing Myelofibrosis: Can We Do More to Address Cytopenias, Reduce Transfusion Burden, and Improve Quality of Life?
Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC
John Papastergiou, BScPhm, PhDc - Human Papillomavirus Head and Neck Cancers: Improving Outcomes in Adults Through Vaccination
Solange Peters, MD, PhD - Advancing Our Patient-Centered Approach to Care in ALK-Positive Metastatic Non-Small Cell Lung Cancer
Brandon M. Meyers, MSc, MD, FRCPC - Raising the Bar in Advanced Hepatocellular Carcinoma Care: Insights to Optimize First-Line Treatment
Michael P. Chu, MD - Chimeric Antigen Receptor T Cells: A New Step in Improving Multiple Myeloma Management
Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?
Gerald Prager, MD - Don't Leave a Drug on the Table: Maximising Use and Benefits of Later-Line Treatments for Advanced Colorectal Cancer
Anna Tinker, BScH, MD, FRCPC - Getting on the Case of Advanced Endometrial Cancer: How Biomarkers May Inform Immunotherapy Treatment Decisions
Robert L. Coleman, MD - New Horizons in Cervical Cancer: Spotlight on Antibody-Drug Conjugates
Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing
Bruno Sangro, MD, PhD - A New Era in the Management of Advanced HCC: Sequencing Therapies for the Second-Line and Beyond
Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time
Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation
Alon Altman, MD, FRCSC - Aiming for Above Par Outcomes in Advanced Ovarian Cancer: The Role of Frontline Maintenance Therapy With PARP Inhibitors
Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC
Stephanie Snow, MD, FRCPC - The Next Frontier in Precision Medicine: Understanding the Role of Liquid Biopsy in Cancer Care
Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns
Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch
Christopher Venner, MD - Insights to Guide Early Recognition and Linkage to Care in AL Amyloidosis: An Expert Discussion
Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?
Julie Stakiw, MD, FRCPC - Clinical Conundrums in CLL: When to Use Continuous Versus Fixed-Duration Treatment
Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat
Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC
The Case for Better Care in Newly Diagnosed Multiple Myeloma: How Can We Improve Outcomes in Challenging Clinical Scenarios?
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
Adjuvant Therapy for Patients With Resected Melanoma: Finessing Care to Improve Survival in High-Risk Patients
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
Starting Strong at First Relapse in Multiple Myeloma: Insights to Guide Treatment Selection in Lenalidomide-Refractory Patients
Strategies to Guide Treatment Selection in Relapsed/Refractory AML: An Expert Discussion
Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias
The Next Frontier in Immunotherapy for Multiple Myeloma: What Will BCMA Targeting Mean for Our Relapsed/Refractory Patients?
Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC
Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022
Making Informed Treatment Choices for the Elderly Patient With CLL: A Look at the Evidence
Gastric Cancer in the Crosshairs: The Evolving Role of Biomarkers and Targeted Therapy in Managing Advanced Gastric Cancer
Managing the Nuances of Paroxysmal Nocturnal Haemoglobinuria: Practical Strategies for Patients Receiving Complement Inhibitors
Immunotherapeutic Approaches in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Insights From the Real World
A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course
Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care
Immunotherapy Combinations for First-Line Advanced NSCLC Treatment: Clinical Insights on Current and Emerging Options
Upping the Ante: Considering Monoclonal Antibodies in Transplant Ineligible Newly Diagnosed Multiple Myeloma
Applying Revised Treatment Guidelines for Advanced Hepatocellular Carcinoma: Considerations in Real-Life Practice
The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer
Case by Case Strategies for Managing the Patient With Relapsed/Refractory Multiple Myeloma in the Clinic
Ensuring Long-Term Success in Advanced Ovarian Cancer: Sequencing Therapy Based on Science
Taking Check of Advanced Non-Melanoma Skin Cancers: Exploring the Clinical Impact of Systemic Immunotherapies
Strategies to Improve Quality of Life in Patients With MDS: Translating the Evidence With Oral HMAs to Practice
Can We Afford Not To? Optimizing Use of G-CSF Biosimilars in Supportive Cancer Care in Canada
Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights from 2021 Virtual Congresses
The Need for Speed: Improving Diagnostic Accuracy and Effective Management of aTTP in Emergency and Intensive Care
Seeking a More Positive Outlook in Patients With mTNBC? Treatment Advances and How to Apply Them
Anti–CD38-Based Regimens for Relapsed/Refractory Multiple Myeloma: Expert Perspectives on the Latest Evidence
An Immune System in Double Trouble: What Is ‘Best Practice’ for Managing Patients With Lymphoproliferative Malignancies?
Therapeutic Sequencing in Patients With Advanced or High Risk Hodgkin Lymphoma: Strategies in Action
Make It a Double? Expert Insights on the Role of Dual Immunotherapy Regimens in First-Line NSCLC Treatment
Treatment Perspectives in HER2-Positive Advanced Breast Cancer: The Role of Novel Therapies in Pretreated Patients
Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses
Fortifying the Treatment of Prostate Cancer With AR-Targeted Therapy: Solidifying Clinical Guidance With Practical Evidence
Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
Navigating the Evolving Therapeutic Landscape of RRMM: Expert Insights on the Latest Advances
Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?
Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)
Treating Anemia in Low- to Intermediate-Risk MDS: Translating the Latest Science into Patient Care
Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold
Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)
Making Treatment of Unresectable HCC Personal: How Individualized Approaches Can Maximize Outcomes
Evaluating the Role of Oral Hypomethylating Agents in MDS: Considerations to Optimize Care
From Bench to Bedside: Evaluating the Role of Maintenance Therapy to Improve Outcomes in Patients With AML
Optimizing Care for Unresectable Malignant Pleural Mesothelioma: Challenges and Solutions
Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)
Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer
Cases in Patient-Centred Care of ITP: Expert Guidance to Optimize Diagnosis and Treatment
Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists
Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy
Addressing Challenges in Lung Cancer Patient Management From Diagnosis to Treatment in a Community Setting
PARP Inhibitors for Recurrent Ovarian Cancer: Leveraging the Latest Tools in the Therapeutic Toolbox to Improve Patient Outcomes
Prevention and Management of Cardiovascular Adverse Events in Multiple Myeloma: Safe and Appropriate Use of Proteasome Inhibitors
"Complementing Evidence With Expert Experience: Challenging Cases in Paroxysmal Nocturnal Haemoglobinuria "
Evolving the Treatment Paradigm in Metastatic HER2-Positive Breast Cancer: The Ongoing Story of Emerging Treatments
Seizing the Moment to Improve Outcomes in Melanoma: When and in Whom Should We Consider Adjuvant Therapy?
Targeting Pro-Tumorigenic Inflammation in NSCLC: Evolving Strategies to Improve Patient Outcomes
Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence
Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management
The Heart of the Matter: An In-Depth Look at the Latest Evidence With CLL Therapies and How to Optimize Treatment Safety
Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data
Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?
Wake Up and Smell the Coffee: Kicking Into Play Novel Treatment Options for Nasal Polyposis
Clearing the Path Forward for Cancer-Associated VTE Treatment: The Role of Direct Oral Anticoagulants in Canadian Practice
The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes
Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease
Suited to a T: Multidisciplinary Perspectives in Identifying and Targeting Key Subtypes of Peripheral T-Cell Lymphoma
Extending Your Interdisciplinary Understanding of IL-6R Inhibitors in Rheumatoid Arthritis
"Optimising the Use of JAK Inhibitors in RA: Translating the Latest Evidence Into Today’s Clinical Practice"
Challenging the Standard of Care in First-Line Advanced HCC Treatment: Breakthroughs With Immunotherapy
Making the Case for Personalized Management in mCSPC: Pertinent Characteristics to Choose the Right Therapy
Managing Patients With Hemophilia A Without Inhibitors in the Era of Non-Replacement Therapy: The Experts Weigh In
Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer
"Case Studies in Locally Advanced and Metastatic CSCC: Integrating Immunotherapy Into Current Treatment Paradigms"
Practical Lessons From Real-World Evidence on CDK 4/6 Inhibitors in Metastatic Breast Cancer
Changing Strategies for Changing Times: Optimising Use of Targeted Alpha Therapies for Advanced Prostate Cancer
Case-Based Approaches to Managing Melanoma: Providing State-of-the-Art Care to Improve Patient Outcomes
Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life Into the Equation
Optimizing Patient-Centred Care With Tumour-Agnostic Strategies: Translating the Evidence With TRK Inhibitors Into Clinical Practice
Drew Provan, MD, FRCP, FRCPath / Caroline Kruse, B.A. - Counting on New Approaches to Improve Outcomes in ITP: Translating Updated Recommendations Into Optimal Patient-Centred Care
A Flitting Target: Guidance on Identifying FLT3 Mutations in Relapsed/Refractory AML to Inform Treatment
Evolving the Treatment Paradigm in HER2-Positive Breast Cancer: Are New Options on the Horizon?
The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?
Evolution of Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Approaches to Management
Gut Check: What New Therapies Mean for the Management of Pretreated, Metastatic Gastric Cancer
Optimizing Care of Patients With ADPKD in Primary Care: Expert Insights to Improve Patient Outcome
Immuno-oncology for mRCC: Considerations for a Combination Approach in the First-Line Setting
Changing Paradigms in Hematologic Malignancies: Translating Early Phase Evidence Into Clinical Practice
Revolutionizing the Treatment of Advanced Breast Cancer: The Expanding Role of CDK4/6 Inhibitors
Raising the Bar With Immunotherapy for Melanoma and Kidney Cancer: Strategies to Enhance Care
Warming Up to Novel Approaches for Primary Cold Agglutinin Disease: Strategies for Correct Diagnosis and Optimal Treatment
Recognizing and Addressing Immune-Related Adverse Events: Key Strategies to Optimize Patient Outcomes With Immunotherapy
Edging Towards a Brighter Long-Term Outlook in NSCLC: Immunotherapy Beyond the First-Line
Raising the Bar in Relapsed/Refractory CLL Care: Translating the Evidence With New and Emerging Therapies to Practice
Prevention and Management of Cardiovascular Adverse Events in Multiple Myeloma: Safe and Appropriate Use of Proteasome Inhibitors
Immunotherapy for First-Line Treatment of Advanced NSCLC: Evolving Options to Refine Care
Maximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes
The Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma
Maximizing Prostate Cancer Outcomes Across Stages of Disease: A Clinical Interpretation of Recent Data
Optimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies
Breathing New Life Into NSCLC Management: Evaluating the Expanding Role of Immunotherapy
Aiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy
Emerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions
Merging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer
Screening and Early Management of Metastatic NSCLC: Updates to Optimize Multidisciplinary Care
Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression
Smoothing the Path After Platinum Chemotherapy: Maximizing Care for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Is There a Cardio-Oncologist in the House? Managing Risk for VTE and Stroke Due to AF in Patients With Cancer
Beyond the Basics: What Do Pharmacists Need to Know About Oncology Therapeutic Biosimilars?
A Practical Guide to Extending Long-Term Survival in Patients With Metastatic Melanoma: A New Era in Medical Strategy
Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Knowledge To Improve Outcomes
Best Practices for Use of Proteasome Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma
To Switch or Not to Switch? Using Asparaginase Activity Testing to Optimize Pediatric ALL Outcomes
Improving Treatment Monitoring and Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
Improving the Long-Term Treatment Plan for Patients With Metastatic Pancreatic Cancer: Insights From San Francisco
The Treatment Plan for Patients With Nonmetastatic Prostate Cancer in Canada: Optimizing the Journey From The Beginning